{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:34:40Z","timestamp":1793169280819,"version":"4.5.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Oncotype DX\u00ae is a validated 21-gene tool for assessing survival benefits of adjuvant chemotherapy for estrogen receptor-positive (ER+)\/human epidermal growth factor receptor 2-negative (HER2\u2212) breast cancer, but its use in core biopsy specimens is limited by costs, access issues, and available tissue volumes, highlighting the need for an alternative to Oncotype DX\u00ae. Therefore, we developed a recurrence score (RS) prediction formula and investigated whether the RS-predicted value calculated from biopsy material could predict pathological complete responses (pCRs) from neoadjuvant chemotherapy (NAC). This retrospective cohort study examined consecutive patients with ER+\/HER2\u2212\u2005primary breast cancer who underwent surgery after NAC at Kitasato Institute Hospital between 2012 and 2023. These values were matched with histological responses to chemotherapy and other clinical and pathological factors. Among 61 patients (median age 54 years), 50% had clinical tumor status 2 tumors, and 40% had node-positive disease. Six patients (9.8%) achieved pCRs, whereas 55 (90.2%) did not. The median RS-predicted value was significantly higher in the pCR group (38.6) than in the non-pCR group (14.0). The pCR rates were 3.8% (2\/53 cases) for RS-predicted values\u2005&lt;\u200526 and 50.0% (4\/8 cases) for RS-predicted values\u2005\u2265\u200526. The optimal RS-predicted cutoff value for predicting pCRs was 33.785, with a sensitivity of 66.7% and a specificity of 98.2%. Higher RS-predicted values calculated from routinely available biopsy biomarkers were associated with a greater likelihood of pCR after NAC in patients with ER+\/HER2\u2212\u2005breast cancer. These preliminary findings suggest that the RS-predicted value may have potential as an accessible tool for predicting the chemotherapy response; however, validation in larger independent cohorts and direct comparisons with the actual Oncotype DX\u00ae RS are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050585","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:07:34Z","timestamp":1789142854000},"page":"e50585","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence score prediction formula based on immunohistochemistry and biopsy data to predict response to neoadjuvant chemotherapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative breast cancer"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2431-7167","authenticated-orcid":false,"given":"Keiichi","family":"Sotome","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Mae","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ogiso","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sako","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobushige","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yanaihara","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriki","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"},{"name":"Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"},{"name":"Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"},{"name":"Department of Pathology, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Suto","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University Kitasato Institute Hospital, Shirokane 5-9-1, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261028","first-page":"CD005002","article-title":"Preoperative chemotherapy for women with operable breast cancer.","volume":"2007","author":"Mieog","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.annonc.2023.04.002","article-title":"Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+\/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+\/HER2- trial.","volume":"34","author":"Gluz","year":"2023","journal-title":"Ann Oncol"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s12282-024-01630-1","article-title":"Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy.","volume":"31","author":"Endo","year":"2024","journal-title":"Breast Cancer"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"264","DOI":"10.31662\/jmaj.2024-0187","article-title":"Design paper: a prospective, multicenter, single-arm, Phase II trial of tailored axillary surgery in patients with clinically node-positive breast cancer in the upfront surgery setting.","volume":"8","author":"Sagara","year":"2025","journal-title":"JMA J"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021.","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"152410","DOI":"10.1016\/j.anndiagpath.2024.152410","article-title":"Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+\/human epidermal growth factor receptor 2 (HER2)- breast cancer.","volume":"74","author":"Sotome","year":"2025","journal-title":"Ann Diagn Pathol"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update.","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12282-013-0460-8","article-title":"Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.","volume":"22","author":"Hida","year":"2015","journal-title":"Breast Cancer"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"e115103","DOI":"10.1371\/journal.pone.0115103","article-title":"The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.","volume":"9","author":"Mao","year":"2014","journal-title":"PLoS One"},{"key":"R18-20261028","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10549-011-1554-7","article-title":"Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.","volume":"132","author":"Ono","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R19-20261028","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"R20-20261028","first-page":"2311","article-title":"Prediction of treatment response to neoadjuvant chemotherapy in breast cancer by subtype using tumor-infiltrating lymphocytes.","volume":"38","author":"Asano","year":"2018","journal-title":"Anticancer Res"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3390\/ijms24032969","article-title":"Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review.","volume":"24","author":"van den Ende","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R22-20261028","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1186\/s12885-020-07654-y","article-title":"Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"key":"R23-20261028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"key":"R24-20261028","doi-asserted-by":"crossref","first-page":"e79775","DOI":"10.1371\/journal.pone.0079775","article-title":"Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer\u2014A substudy of the neoadjuvant GeparQuinto trial.","volume":"8","author":"Issa-Nummer","year":"2013","journal-title":"PLoS One"},{"key":"R25-20261028","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12094-015-1391-y","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.","volume":"18","author":"Yu","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"R26-20261028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"R27-20261028","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/PAI.0000000000000466","article-title":"Prognostic significance of stromal versus intratumoral infiltrating lymphocytes in different subtypes of breast cancer treated with cytotoxic neoadjuvant chemotherapy.","volume":"26","author":"Khoury","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R28-20261028","doi-asserted-by":"crossref","first-page":"e0300339","DOI":"10.1371\/journal.pone.0300339","article-title":"A randomised controlled trial of pre-operative Oncotype DX testing in early-stage breast cancer (PRE-DX study)\u2014Study protocol.","volume":"19","author":"Northgraves","year":"2024","journal-title":"PLoS One"},{"key":"R29-20261028","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1200\/JCO.2005.02.0818","article-title":"Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.","volume":"23","author":"Gianni","year":"2005","journal-title":"J Clin Oncol"},{"key":"R30-20261028","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10549-021-06269-6","article-title":"Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy.","volume":"189","author":"Ma","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"R31-20261028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.breast.2021.01.001","article-title":"Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.","volume":"56","author":"Morales Murillo","year":"2021","journal-title":"Breast"},{"key":"R32-20261028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/bjs\/znaa048","article-title":"Value of a 21-gene expression assay on core biopsy to predict neoadjuvant chemotherapy response in breast cancer: systematic review and meta-analysis.","volume":"108","author":"Boland","year":"2021","journal-title":"Br J Surg"},{"key":"R33-20261028","doi-asserted-by":"crossref","first-page":"102323","DOI":"10.1016\/j.ctrv.2021.102323","article-title":"Gene-expression signatures to inform neoadjuvant treatment decision in HR+\/HER2- breast cancer: available evidence and clinical implications.","volume":"102","author":"Griguolo","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R34-20261028","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","article-title":"Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.","volume":"91","author":"Ring","year":"2004","journal-title":"Br J Cancer"},{"key":"R35-20261028","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: THE GEPARDUO study of the German Breast Group.","volume":"23","author":"von Minckwitz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24 Pt 1","key":"R36-20261028","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/1078-0432.CCR-05-0539","article-title":"Feasibility and tolerability of sequential doxorubicin\/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.","volume":"11","author":"Gianni","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R37-20261028","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"R38-20261028","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/ijerph20021617","article-title":"Development and assessment of a novel core biopsy-based prediction model for pathological complete response to neoadjuvant chemotherapy in women with breast cancer.","volume":"20","author":"Lan","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R39-20261028","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown.","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"key":"R40-20261028","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/bcr1989","article-title":"Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.","volume":"10","author":"von Minckwitz","year":"2008","journal-title":"Breast Cancer Res"},{"key":"R41-20261028","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10549-009-0329-x","article-title":"Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.","volume":"119","author":"Jones","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R42-20261028","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2217\/fon-2016-0420","article-title":"The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.","volume":"13","author":"Chen","year":"2017","journal-title":"Future Oncol"},{"key":"R43-20261028","doi-asserted-by":"crossref","first-page":"1323226","DOI":"10.3389\/fonc.2024.1323226","article-title":"A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer.","volume":"14","author":"Fang","year":"2024","journal-title":"Front Oncol"},{"key":"R44-20261028","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11596-023-2824-4","article-title":"Ki-67 change in anthracyline-containing neoadjuvant chemotherapy response in breast cancer.","volume":"44","author":"Yang","year":"2024","journal-title":"Curr Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:00:48Z","timestamp":1793167248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050585"}},"subtitle":["A retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":43,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050585","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2025-07-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}